Siegfried opens drug substances R&D centre

Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz. The 4,500 m² centre houses chemical and analytical facilities, laboratories and advanced technologies including flow chemistry, distillation and process analytics, plus office space. There are workspaces for over 100 and 40 new jobs have been created.

This came only weeks after Siegfried’s Dinamiqs subsidiary had opened its own new laboratories at Bio-Technopark in Zurich. This features pilot-scale equipment for clinical viral vector development, as well as analytical and manufacturing services for cell and gene therapy. It is part of a 2,500 m² cGMP manufacturing facility for viral vectors, which is currently under construction and set to be operational by the end of 2025.